Table 2. Data regarding the treatment and tumor burden of the study population.
Results are expressed as n(%) or median (interquartile range).
*: Statistically significant value.
T2DM = type 2 diabetes mellitus; CT = chemotherapy
| Characteristics | Whole population (n = 187) | No T2DM (n = 133) | T2DM (n = 54) | P-value |
| Metastatic involvement, n (%) | ||||
| One site | 109 (58.3) | 90 (67.7) | 19 (35.2) | <0.01* |
| Two sites | 57 (30.5) | 33 (24.8) | 24 (44.4) | |
| > two sites | 21 (11.2) | 10 (7.5) | 11 (20.4) | |
| First-line backbone CT, n (%) | ||||
| FOLFIRI | 77 (41.2) | 53 (39.8) | 24 (44.4) | 0.68 |
| FOLFOX | 86 (46.0) | 62 (46.6) | 24 (44.4) | 0.91 |
| Capecitabine | 19 (10.2) | 13 (9.8) | 6 (11.1) | 0.99 |
| FOLFOXIRI | 5 (2.6) | 5 (3.8) | 0 (0.0) | 0.32 |
| Number of CT lines, n (%) | ||||
| One | 58 (31.0) | 36 (27.1) | 22 (40.7) | 0.02* |
| Two | 76 (40.6) | 51 (38.4) | 25 (46.3) | |
| Three | 36 (19.3) | 31 (23.3) | 5 (9.3) | |
| More than three lines | 17 (9.1) | 15 (11.3) | 2 (3.7) | |
| No | 119 (63.6) | 84 (63.2) | 35 (64.8) | |